|
AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly traded company listed on NASDAQ under the symbol "AMAG". == Operations == AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.〔(【引用サイトリンク】 title=AMAG Profile )〕 AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of in 2013. In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020. In June 2015 the company acquired Cord Blood Registry for $700 million. 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「AMAG Pharmaceuticals」の詳細全文を読む スポンサード リンク
|